Evidence map›Paper›PMID 38976318›Full record

ArticleCancer communications (London, England)2024

SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.

Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan and 26 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Shuqui QinDepartment of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China.
Jin LiDepartment of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China.ORCID 0000-0003-0099-874X
Aiping ZhouDepartment of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.
Yanqiao ZhangDepartment of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.
Xianglin YuanDepartment of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
Liangjun ZhuDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.
Baoli QinDepartment of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.ORCID 0000-0002-0988-723X
Lin ShenDepartment of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
Ying YuanDepartment of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.ORCID 0000-0002-3922-9553
Weibo WangDepartment of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China.
Jun LiangDepartment of Medical Oncology, Peking University International Hospital, Beijing, P. R. China.
Xianwen ZhangDepartment of Medical Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, P. R. China.
Feng YeDepartment of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China.
Ping ChenDepartment of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China.
Huaizhang WangDepartment of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
Zhenyan YuDepartment of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China.
Lu YueDepartment of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China.
Yong FangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
Jianping XiongDepartment of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.
Jianwei YangDepartment of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.
Yiye WanDepartment of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.
Xianli YinDepartment of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
Wenling WangDepartment of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China.
Nong XuDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
Xiaohong WangDepartment of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
Zemin XiaoDepartment of Oncology, The First People's Hospital of Changde City, Changde, Hunan, P. R. China.
Huafang SuDepartment of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.
Ying WangDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
Kangsheng GuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
Shuiping TuDepartment of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Zishu WangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China.
Bo LiuDepartment of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China.
Xiaohua HuDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.
Weixian LiuDepartment of Medical Oncology, Binzhou People's Hospital, Binzhou, Shandong, P. R. China.
Xiaofeng LiDepartment of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsIrinotecanQuinazolinesRegistriesAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisProspective StudiesThiophenesIrinotecanQuinazolinesraltitrexedThiophenes

Identifiers

PMID38976318
PMCPMC11337918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.